Report
Pharma Mar : Q3: weak oncology offset by a € 9m milestone. Updating our valuation with lurbi’s 1L potential
>Core business momentum remains soft on overprovision reversals - Sales increased 22% y-o-y in Q3 2024 (vs -7% in Q2, +12% in Q1 and -20% in Q4). Biopharma sales decreased 5% y-o-y in Q3 2024 (compared to -18% in Q2, +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect, 9M 2024 Lurbi sales in Europe are growing at a +14% pace (vs +16% in H1). Royalties post...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.